Atrial Fibrillation Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older.
• People who have been diagnosed with symptomatic paroxysmal atrial fibrillation (an irregular heart rhythm that starts and stops on its own or with treatment within 7 days), with at least 2 symptomatic episodes in the past 6 months and at least 1 episode confirmed by a heart tracing (ECG or Holter monitor) in the past 12 months.
• People who have been diagnosed with persistent atrial fibrillation (an irregular heart rhythm lasting more than 7 days but no longer than 365 days), with at least 1 symptomatic episode in the past 6 months and confirmed by heart monitoring records in the past 12 months.
• People for whom at least one heart rhythm medication has not worked well enough or has caused intolerable side effects.
• People who are scheduled to have a heart procedure called pulsed field ablation.
• People who are willing and able to sign a consent form agreeing to take part.
• People who are able to attend in-hospital assessments and follow-up appointments at 30 days and 90 days.

Who may not be able to join:

• People whose atrial fibrillation is caused by a treatable condition, such as an overactive thyroid or a recent surgery.
• People who have not been taking blood-thinning medication for at least 3 weeks before the ablation procedure.
• People who have a blood clot inside the heart.
• People who cannot take blood-thinning medication or who have a known reaction to iodine-based contrast dye used in imaging.
• People with significant heart valve problems, such as moderate or severe narrowing or leaking of the aortic or mitral valves.
• People who have had a heart attack within the past 3 months.
• People who have had heart surgery within the past 3 months.
• People with moderately severe or severe heart failure (classified as NYHA class III or IV).
• People whose heart pumping function is significantly reduced (ejection fraction below 35%).
• People diagnosed with a thickened heart muscle condition called hypertrophic cardiomyopathy.
• People with severe liver disease (confirm with trial site for scoring details).
• People with advanced chronic kidney disease (stage 4 or 5, with a kidney filtration rate below 30 mL/min/1.73 m²).
• People who have had a kidney transplant.
• People who are currently on or have previously required dialysis or other kidney replacement therapy.
• People who have received iodine-based contrast dye within 7 days before enrolling.
• People with an active infection anywhere in the body.
• People who are pregnant or breastfeeding.
• People who are already participating in another clinical trial that could affect this study's results.
• People who are unlikely or unwilling to follow the study procedures and attend follow-up visits, as assessed by the trial investigator.

Important: Always verify eligibility with the trial site directly before applying.